Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Bexxar: encouraging interim phase III data reported

May 14, 1998

DAB389IL-7, a novel fusion protein for the specific elimination of IL-7 receptor-positive cells

May 12, 1998

Patient enrollment begins for U.S. trial of Maxamine in malignant melanoma

May 11, 1998

Multikine clinical trials update

May 11, 1998

Genentech files for marketing approval of Herceptin

May 5, 1998

Biomira initiates bridging study of Theratope cancer vaccine

May 4, 1998

Efficacy of StressGen's HspE7 in preclinical cancer models reported at FASEB 98

April 28, 1998

Cytokine Networks to initiate clinical trial of anticancer vaccine

April 24, 1998

Schering-Plough seeks FDA approval for Intron A combination

April 20, 1998

Mechanism of cytotoxic effect of ImmTher

April 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
Shanghai Yingli Pharmaceutical identifies new KRAS mutant inhibitors
BioWorld Science
Shanghai Yingli Pharmaceutical Co. Ltd. has discovered hydrazine-structured compounds as inhibitors of GTPase KRAS and its mutants. They are reported to be useful...